SOT is effective at treating cancer in 77% of patients

A newly published study by RGCC scientists has found that cancer patients treated with the highly targeted supportive oligonucleotide therapy (SOT) showed benefits in 77% of cases.

SOT is an advanced, personalized form of cancer treatment that disrupts how cancer cells replicate or survive.

A new paper published in the Vivo journal finds evidence that SOTs effectively target and kill cancer cells on their own.